- Home
- STTK vs SER Comparison
STTK vs SER Comparison
Compare STTK & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- SER
- Stock Information
- Founded
- STTK 2016
- SER 2017
- Country
- STTK United States
- SER United States
- Employees
- STTK N/A
- SER N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- SER Health Care
- Exchange
- STTK Nasdaq
- SER Nasdaq
- Market Cap
- STTK 59.7M
- SER 54.3M
- IPO Year
- STTK 2020
- SER 2018
- Fundamental
- Price
- STTK $1.24
- SER $4.83
- Analyst Decision
- STTK Hold
- SER
- Analyst Count
- STTK 3
- SER 0
- Target Price
- STTK $2.00
- SER N/A
- AVG Volume (30 Days)
- STTK 357.1K
- SER 17.4K
- Earning Date
- STTK 11-14-2024
- SER 11-12-2024
- Dividend Yield
- STTK N/A
- SER N/A
- EPS Growth
- STTK N/A
- SER N/A
- EPS
- STTK N/A
- SER N/A
- Revenue
- STTK $6,435,000.00
- SER $3,156,637.00
- Revenue This Year
- STTK $115.09
- SER N/A
- Revenue Next Year
- STTK N/A
- SER N/A
- P/E Ratio
- STTK N/A
- SER N/A
- Revenue Growth
- STTK 382.75
- SER 2436.14
- 52 Week Low
- STTK $1.07
- SER $3.81
- 52 Week High
- STTK $11.76
- SER $19.93
- Technical
- Relative Strength Index (RSI)
- STTK 38.29
- SER 33.74
- Support Level
- STTK $1.14
- SER $3.81
- Resistance Level
- STTK $1.56
- SER $5.79
- Average True Range (ATR)
- STTK 0.12
- SER 0.79
- MACD
- STTK 0.07
- SER -0.13
- Stochastic Oscillator
- STTK 24.42
- SER 25.89
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.